The great ambivalence: factors likely to affect service user and public acceptability of the pharmacogenomics of antidepressant medication
Authors:
- 28 August 2008
- journal article
- Published by Wiley in Sociology of Health & Illness
- Vol. 30 (6) , 944-958
Abstract
Whilst antidepressant medications are widely used, they are ineffective for nearly 40 per cent of users and cause numerous adverse drug reactions. The pharmacogenomics of depression attempts to better understand the role of genetic variation in antidepressant metabolism in the hope of improving drug efficacy and tolerability. In this paper we present findings from a series of focus groups with the general public and with mental health service users in four European sites. Results indicate broad support for genome‐based therapies for depression. Findings, however, also show a wide spread of ambivalence regarding the nature and causes of depression, as well as the use of antidepressant medication. We argue that these uncertainties may negatively impact public and user acceptability of the pharmacogenomics of antidepressants.Keywords
This publication has 19 references indexed in Scilit:
- Is It Me or My Meds?2006
- The Politics of Personalised Medicine2004
- Pharmacogenetic Testing, Informed Consent and the Problem of Secondary InformationBioethics, 2004
- The Drugs Don't WorkSocial Studies of Science, 2003
- Pharmaceutical industry is main influence in GP prescribingBMJ, 2003
- Hope Against Hype - Accountability in Biopasts, Presents and FuturesScience & Technology Studies, 2003
- The impact of pharmacogenetics and pharmacogenomics on drug discoveryNature Reviews Drug Discovery, 2002
- The distinction between mental and physical illnessThe British Journal of Psychiatry, 2001
- Effects of Client Interviewers on Client-Reported Satisfaction With Mental Health ServicesPsychiatric Services, 1999
- The methodology of Focus Groups: the importance of interaction between research participantsSociology of Health & Illness, 1994